Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.
LeBlanc R, Ahmad I, Terra R, Boudreault JS, Ogez D, Lamore K, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Lemieux-Blanchard É, Sauvageau G, Sebag M, Roy DC, Roy J.
LeBlanc R, et al. Among authors: lamore k.
Bone Marrow Transplant. 2022 Feb;57(2):252-260. doi: 10.1038/s41409-021-01532-2. Epub 2021 Nov 29.
Bone Marrow Transplant. 2022.
PMID: 34845367
Clinical Trial.